eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2016-03-31 13 1 287 297 10.13005/bbra/2032 7748 article Amr Amin 1,2 Mohammed Mukhtar 1 Essam Noor Eldin 1 Fahd Gethami 3 Fayez Hafez 3 Sameer Fatani 1 Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt King Faisal Hospitals, Shesha, Makkah, Kingdom of Saudi Arabia Medical Genetics department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia Division of Human Genetics and Genome Research, Department of Molecular Genetics and Enzymology, National Research Centre, 33Bohouth St. Dokki, Giza, Egypt Hepatic fibrosis detection is considered as a major independent predictor of treatment response in patients with chronic hepatitis C virus (HCV). Liver biopsy was represented as the gold standard method for evaluating liver fibrosis and has prone sampling errors and completions. Right now, usages of non-invasive predictors of fibrosis are considered less accurate than liver biopsy. We are aiming to reduce the use of the liver biopsy and instead evaluate the performance value of serum hyaluronic acid (HA), Collagen type IV (Coll-IV), and aspartate aminotransferase (AST) to platelet ratio index (APRI) as non-invasive diagnostic and stratification markers for hepatic fibrosis. In this study, we have recruited 104 subjects from Saudi population effected with chronic hepatitis C genotype 4. The enzyme-linked immunosorbent assay (ELISA) method was implemented for Liver histopathological staging (F), serum hyaluronic acid and Collagen-IV. APRI was calculated from serum AST activity and platelet count. The results of our current study indicated both Collagen-IV and APRI significantly distinguished fibrotic patients from non-fibrotic group. The HA, APRI, and Coll-IV results discriminate early F0/F1 from F2/F3 (p<0.001). A combination of direct and indirect tests (Coll-IV and APRI) improved the performance with sensitivity and specificity. The combination of APRI and Collagen-IV has a high diagnostic value in predicting moderate and severe fibrotic stages and could be clinically used as a diagnostic test especially for those HCV patients who could not be submitted for liver biopsy. https://www.biotech-asia.org/vol13no1/prediction-of-hepatic-fibrosis-in-patients-with-chronic-hepatitis-c-genotype-4-a-non-invasive-biochemical-analysis/ Hepatic fibrosis; chronic hepatitis C; HCV genotype 4; serum hyaluronic acid (HA); serum Collagen type IV (Coll-IV); AST to platelet ratio index (APRI); Receiver operating characteristics